2014-04-29 02:20:04 - Aptamers Market: Global Forecasts to 2018 - a new market research report on companiesandmarkets.com
The global aptamers market is suggested to have reached a value of around $200 million at the end of 2012, and is estimated to reach over $287 million by the end of 2013. The current forecast suggests that by 2018 the industry will be worth over $2.1 billion. Growth is forecast to be seen is all application areas, including therapeutics and disgnostics.
Aptamers is an emerging market, widely considered as a rival or substitute to antibodies in the scientific industry. Aptamers existed in parallel with antibodies for two decades, but its market potential was not utilized, even to a fraction of antibodies. However, the achievement of Macugen has given a boost to the aptamer field. The list of promising aptamers in
the clinical trials pipeline estimates that these synthetic chemical antibodies will soon surpass monoclonal antibodies in therapeutics, diagnosis, and imaging. With technological merits over antibodies, the aptamers market is poised to grow at par with antibodies in the next 10-15 years.
North America is a significant contributor to the market, followed by Europe, due to the presence of technology providers and better R&D facilities. The new markets that are expected to grow at a brisk pace are emerging economics such as China, India, Japan and other regions of Asia-Pacific and untapped markets of Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.
The biomarker discovery, drug discovery and diagnostics segments offer vast opportunities for key players in this market. The launch of the first aptamer drug, Macugen, and the first diagnostic test for testing mycotoxins in grains has acknowledged the potential of aptamers in therapeutics and diagnostics. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years.
The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests.
Key players in this market are AM Biotechnologies, LLC (U.S.), Aptagen, LLC (U.S.), Aptamer Sciences Inc. (South Korea), Aptamer Solutions Ltd (U.K.), Base Pair Biotechnologies (U.S.), Bioapter S.L. (Spain), Integrated Biotechnologies, Inc. (U.S.), NOXXON Pharma AG (Germany), OTC Biotech (U.S.), Regado Biosciences, Inc. (U.S.), Somalogic, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.